IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.658
EU - Europa 6.808
AS - Asia 6.201
SA - Sud America 1.502
Continente sconosciuto - Info sul continente non disponibili 503
AF - Africa 123
OC - Oceania 6
Totale 22.801
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.192
RU - Federazione Russa 3.614
SG - Singapore 2.183
CN - Cina 1.723
IT - Italia 1.358
BR - Brasile 1.192
HK - Hong Kong 686
VN - Vietnam 668
SE - Svezia 495
BD - Bangladesh 436
FR - Francia 301
RO - Romania 278
CA - Canada 224
DE - Germania 203
GB - Regno Unito 187
IN - India 134
AR - Argentina 127
MX - Messico 92
NL - Olanda 78
ID - Indonesia 59
FI - Finlandia 56
JP - Giappone 53
PL - Polonia 51
ZA - Sudafrica 50
EC - Ecuador 49
AT - Austria 48
CO - Colombia 40
TR - Turchia 36
ES - Italia 35
IQ - Iraq 34
CR - Costa Rica 26
JM - Giamaica 26
VE - Venezuela 25
CL - Cile 24
MA - Marocco 22
LT - Lituania 19
MY - Malesia 19
NI - Nicaragua 19
PY - Paraguay 18
AE - Emirati Arabi Uniti 16
HN - Honduras 15
IE - Irlanda 15
PH - Filippine 15
SA - Arabia Saudita 14
UA - Ucraina 14
UZ - Uzbekistan 14
PK - Pakistan 13
EG - Egitto 12
DZ - Algeria 11
IR - Iran 11
TT - Trinidad e Tobago 11
AZ - Azerbaigian 10
NP - Nepal 10
UY - Uruguay 10
GT - Guatemala 9
BB - Barbados 8
PR - Porto Rico 8
BO - Bolivia 7
KE - Kenya 7
MD - Moldavia 7
PE - Perù 7
SV - El Salvador 7
TW - Taiwan 7
AU - Australia 6
BE - Belgio 6
BH - Bahrain 6
CH - Svizzera 6
IL - Israele 6
KR - Corea 6
KZ - Kazakistan 6
LB - Libano 6
OM - Oman 6
BA - Bosnia-Erzegovina 5
TN - Tunisia 5
AO - Angola 4
BG - Bulgaria 4
EU - Europa 4
GP - Guadalupe 4
KG - Kirghizistan 4
TH - Thailandia 4
BM - Bermuda 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
JO - Giordania 3
KW - Kuwait 3
PA - Panama 3
PT - Portogallo 3
QA - Qatar 3
SI - Slovenia 3
A1 - Anonimo 2
AL - Albania 2
BS - Bahamas 2
CG - Congo 2
CY - Cipro 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
Totale 22.279
Salva come PNG Salva come JPEG
Città #
Dallas 1.567
Singapore 1.122
Ashburn 847
Moscow 767
San Jose 697
Hong Kong 676
New York 384
Beijing 332
Council Bluffs 328
Milan 320
Ho Chi Minh City 254
Shanghai 246
Lauterbourg 232
Hefei 220
Los Angeles 176
Santa Clara 174
Princeton 150
Lawrence 149
Phoenix 130
Hanoi 128
São Paulo 100
Rome 98
Orem 69
Boardman 63
Chicago 59
Naples 56
Atlanta 52
Montreal 52
Nuremberg 50
London 45
Miano 45
Brooklyn 44
Tokyo 43
Warsaw 43
Rio de Janeiro 41
Helsinki 39
Mexico City 37
Toronto 37
Boston 35
Da Nang 35
Denver 34
Guangzhou 34
Munich 34
Belo Horizonte 32
Buffalo 32
Poplar 32
Houston 31
Stockholm 31
Vienna 30
Chennai 27
Cesano Boscone 26
Porto Alegre 26
Frankfurt am Main 25
Johannesburg 25
Haiphong 24
North Bergen 24
Manchester 23
Mumbai 23
Amsterdam 22
Bologna 22
Brasília 22
Biên Hòa 21
Kingston 21
Washington 21
Guarulhos 20
Philadelphia 20
Curitiba 19
San José 19
Ankara 18
Bari 18
Brescia 18
Columbus 18
Managua 18
Miami 18
Newark 18
Seattle 18
Shenzhen 18
Dhaka 17
Florence 17
Charlotte 16
Lappeenranta 16
New Delhi 16
Quito 16
San Francisco 16
Turin 16
The Dalles 15
Tianjin 15
Palermo 14
Romagnano Sesia 14
Tashkent 14
Calgary 13
Cleveland 13
Guayaquil 13
Baghdad 12
Catania 12
Changsha 12
Dublin 12
Figino 12
Hải Dương 12
Querétaro 12
Totale 11.149
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 446
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments 446
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 429
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 361
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 178
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 176
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 167
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 160
Comparing Liver Venous Deprivation and Portal Vein Embolization for Perihilar Cholangiocarcinoma: Is It Time to Shift the Focus to Hepatic Functional Reserve Rather than Hypertrophy? 159
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 148
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 143
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 142
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 141
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 137
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 135
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 134
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 133
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 132
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments 132
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 130
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 130
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 126
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 126
Correction to: Prospective minimally invasive pancreatic resections from the IGOMIPS registry: a snapshot of daily practice in Italy on 1191 between 2019 and 2022 (Updates in Surgery, (2023), 75, 6, (1439-1456), 10.1007/s13304-023-01592-7) 125
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 125
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 124
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 124
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 122
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 121
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 121
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 118
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 117
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 116
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 115
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 115
Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review 114
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 114
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 113
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 113
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 113
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 112
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 110
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 108
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming 108
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 108
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 107
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 106
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 106
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 106
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 104
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 104
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 104
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 101
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 100
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes 100
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 100
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 99
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 99
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 99
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 99
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 99
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 99
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 98
EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY 97
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 97
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 96
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 95
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 95
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 95
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma 94
Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA) 94
Cholangiocarcinoma: new perspectives for new horizons 94
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 93
Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study 93
A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study 93
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 92
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 92
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 92
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 92
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 91
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 91
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 90
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 89
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 89
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 88
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 87
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 87
BRAF-mutated colorectal cancer: Clinical and molecular insights 86
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 85
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 84
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 84
Over-the-Wire Lumen-Apposing Metal Stent Exchange for Management of a Long-Term Choledochoduodenostomy Dysfunction 84
Platelets and hepatocellular cancer: Bridging the bench to the clinics 84
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 84
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 84
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 83
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 83
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 82
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials 82
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 80
Totale 12.098
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024673 35 18 58 54 33 226 75 47 0 11 30 86
2024/20253.046 349 70 73 33 67 254 687 289 397 281 193 353
2025/202614.436 935 1.392 1.551 1.888 1.027 433 958 947 3.362 601 613 729
2026/20273.574 691 863 832 1.188 0 0 0 0 0 0 0 0
Totale 22.801